Tomasz Beer is an Oncology physician affiliated with Oregon Health & Science University. OpenAlex indexes 802 publications with 38,299 citations (h-index 82); ClinicalTrials.gov lists 17 registered studies matched to this name. By OpenAlex citation count, this profile ranks in the top 10% of Medical Oncology profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3181 SW Sam Jackson Park Rd
Portland, OR 972393011
Telephone
503-494-6594Registry record last updated 20 Jul 2007.
Clinical trials
- Falcon Real World Evidence Registry
Sponsor: Exact Sciences Corporation
- Pre-Prostatectomy Celecoxib or Placebo
Sponsor: OHSU Knight Cancer Institute
- Dietary Fat Levels and Abiraterone Acetate Uptake in Patients With Metastatic Hormone-Resistant Prostate Cancer
Sponsor: OHSU Knight Cancer Institute
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
9 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca UK LimitedProgram year20252 payments
- AstraZeneca UK LimitedProgram year20243 payments
- PFIZER INC.Program year20242 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
91.7%Androgen Receptor Inhibitor38.1%Xtandi77%Bicalutamide23%Part D<11 patientsCytochrome P450 17A1 Inhibitor27.9%Abiraterone Acetate100%Part D<11 patients+ 2 more classes in this area
Metabolism & gastrointestinal
8.3%Corticosteroid8.3%Prednisone100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
8 NIH research awards on record, funded 2000–2009 per NIH RePORTER. The latest:
- Resistance and Response Mechanisms to Prostate Cancer Therapy
Oregon Health & Science University
FY2009$337,853R01CA119125 - Resistance and Response Mechanisms to Prostate Cancer Therapy
Oregon Health & Science University
FY2008$340,148R01CA119125
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
New England Journal of Medicine
2021
Similar KOLs
Other experts from the same institution or the same specialty.
Eric Orwoll, MD
Oregon Health & Science University
Aaron Caughey, MD
Oregon Health & Science University
John Nutt, MD
Oregon Health & Science University
Richard Maziarz, MD
Oregon Health & Science University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”